blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2911691

EP2911691 - METHODS OF TREATING NEUROENDOCRINE TUMORS USING WNT PATHWAY-BINDING AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.08.2019
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  07.09.2018
FormerGrant of patent is intended
Status updated on  24.04.2018
FormerExamination is in progress
Status updated on  17.02.2017
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, HU, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
OncoMed Pharmaceuticals, Inc.
800 Chesapeake Drive
Redwood City, CA 94063 / US
[2015/36]
Inventor(s)01 / STAGG, Robert, Joseph
2 Silvia Court
Moraga, CA 94556 / US
02 / DUPONT, Jacob
1229 Cardigan Road
Hillsborough, CA 94010 / US
 [2015/36]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2015/36]Sutcliffe, Nicholas Robert, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date13848322.722.10.2013
[2015/36]
WO2013US66087
Priority number, dateUS201261717294P23.10.2012         Original published format: US 201261717294 P
US201361760529P04.02.2013         Original published format: US 201361760529 P
[2015/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014066328
Date:01.05.2014
Language:EN
[2014/18]
Type: A1 Application with search report 
No.:EP2911691
Date:02.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 01.05.2014 takes the place of the publication of the European patent application.
[2015/36]
Type: B1 Patent specification 
No.:EP2911691
Date:10.10.2018
Language:EN
[2018/41]
Search report(s)International search report - published on:US01.05.2014
(Supplementary) European search report - dispatched on:EP25.04.2016
ClassificationIPC:A61K39/395, C12N15/11, A61P35/00, C07K16/28
[2016/21]
CPC:
C07K16/3053 (EP,US); A61K39/39558 (US); A61K38/177 (US);
A61K45/06 (EP,US); A61P35/00 (EP); A61P43/00 (EP);
C07K14/705 (US); C07K16/28 (EP,US); C07K16/2863 (EP,US);
A61K2039/505 (EP,US); C07K2317/21 (EP,US); C07K2317/56 (US);
C07K2317/565 (US); C07K2317/76 (EP,US); C07K2319/02 (US);
C07K2319/30 (US); C07K2319/32 (US) (-)
C-Set:
A61K39/395, A61K2300/00 (EP,US)
Former IPC [2015/36]A61K39/395, C12N15/11
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/36]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON NEUROENDOKRINEN TUMOREN MIT WNT-PAD-BINDEMITTELN[2015/36]
English:METHODS OF TREATING NEUROENDOCRINE TUMORS USING WNT PATHWAY-BINDING AGENTS[2015/36]
French:MÉTHODES DE TRAITEMENT DE TUMEURS NEURO-ENDOCRINES À L'AIDE D'AGENTS LIANTS DE PARCOURS WNT[2015/36]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase28.04.2015National basic fee paid 
28.04.2015Search fee paid 
28.04.2015Designation fee(s) paid 
28.04.2015Examination fee paid 
Examination procedure28.04.2015Examination requested  [2015/36]
22.11.2016Amendment by applicant (claims and/or description)
17.02.2017Despatch of a communication from the examining division (Time limit: M04)
16.06.2017Reply to a communication from the examining division
11.10.2017Despatch of a communication from the examining division (Time limit: M04)
24.01.2018Reply to a communication from the examining division
27.03.2018Despatch of a communication from the examining division (Time limit: M04)
28.03.2018Reply to a communication from the examining division
25.04.2018Communication of intention to grant the patent
03.09.2018Fee for grant paid
03.09.2018Fee for publishing/printing paid
03.09.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.02.2017
Opposition(s)11.07.2019No opposition filed within time limit [2019/38]
Fees paidRenewal fee
27.10.2015Renewal fee patent year 03
11.10.2016Renewal fee patent year 04
11.10.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.10.2013
AL10.10.2018
AT10.10.2018
CY10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
MK10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
SM10.10.2018
TR10.10.2018
IE22.10.2018
LU22.10.2018
MT22.10.2018
BE31.10.2018
CH31.10.2018
LI31.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
[2020/31]
Former [2020/17]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
SM10.10.2018
TR10.10.2018
IE22.10.2018
LU22.10.2018
MT22.10.2018
BE31.10.2018
CH31.10.2018
LI31.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2020/08]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
SM10.10.2018
IE22.10.2018
LU22.10.2018
MT22.10.2018
BE31.10.2018
CH31.10.2018
LI31.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/50]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SI10.10.2018
SK10.10.2018
SM10.10.2018
IE22.10.2018
LU22.10.2018
BE31.10.2018
CH31.10.2018
LI31.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/48]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SK10.10.2018
SM10.10.2018
IE22.10.2018
LU22.10.2018
BE31.10.2018
CH31.10.2018
LI31.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/40]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SK10.10.2018
SM10.10.2018
LU22.10.2018
BE31.10.2018
CH31.10.2018
LI31.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/38]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SM10.10.2018
LU22.10.2018
BE31.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/37]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
EE10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
MC10.10.2018
NL10.10.2018
PL10.10.2018
RO10.10.2018
RS10.10.2018
SE10.10.2018
SM10.10.2018
LU22.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/35]AL10.10.2018
AT10.10.2018
CZ10.10.2018
DK10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
NL10.10.2018
PL10.10.2018
RS10.10.2018
SE10.10.2018
LU22.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/34]AL10.10.2018
AT10.10.2018
DK10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
IT10.10.2018
LT10.10.2018
LV10.10.2018
NL10.10.2018
PL10.10.2018
RS10.10.2018
SE10.10.2018
LU22.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/30]AL10.10.2018
AT10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
LT10.10.2018
LV10.10.2018
NL10.10.2018
PL10.10.2018
RS10.10.2018
SE10.10.2018
LU22.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/26]AL10.10.2018
AT10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
LT10.10.2018
LV10.10.2018
NL10.10.2018
PL10.10.2018
RS10.10.2018
SE10.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
PT10.02.2019
Former [2019/25]AT10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
LT10.10.2018
LV10.10.2018
NL10.10.2018
PL10.10.2018
RS10.10.2018
SE10.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
Former [2019/24]AT10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
LT10.10.2018
LV10.10.2018
NL10.10.2018
PL10.10.2018
SE10.10.2018
BG10.01.2019
NO10.01.2019
GR11.01.2019
IS10.02.2019
Former [2019/23]AT10.10.2018
ES10.10.2018
FI10.10.2018
HR10.10.2018
LT10.10.2018
LV10.10.2018
NL10.10.2018
PL10.10.2018
BG10.01.2019
NO10.01.2019
IS10.02.2019
Former [2019/22]FI10.10.2018
LT10.10.2018
NL10.10.2018
PL10.10.2018
BG10.01.2019
NO10.01.2019
IS10.02.2019
Former [2019/21]FI10.10.2018
LT10.10.2018
NL10.10.2018
NO10.01.2019
IS10.02.2019
Former [2019/20]LT10.10.2018
NL10.10.2018
NO10.01.2019
Former [2019/17]NL10.10.2018
Documents cited:Search[I]WO2008031009  (GENENTECH INC [US], et al) [I] 1-20 * page 99 - page 102 *;
 [XI]WO2010037041  (ONCOMED PHARM INC [US], et al) [X] 1,2,6,14,20 * paragraph [0374]; examples 12,13,15-18 * [I] 1-20;
 [XI]US2011020368  (HYNES NANCY [CH]) [X] 1,2,6,14,20 * paragraphs [0014] , [0017] - paragraph [0020] * * paragraph [0137] * [I] 1-20;
 [I]WO2012003189  (IRM LLC [US], et al) [I] 1-20 * paragraphs [0057] , [0083] - paragraph [0084] * * the whole document *;
 [XI]  - A. GURNEY ET AL, "Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20120702), vol. 109, no. 29, doi:10.1073/pnas.1120068109, ISSN 0027-8424, pages 11717 - 11722, XP055204893 [X] 1,2,6,7,14,20 * page 11719, column l, paragraph 1 - page 17120, column l, paragraph l * [I] 1-20

DOI:   http://dx.doi.org/10.1073/pnas.1120068109
 [I]  - N PODE-SHAKKED ET AL, "Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target", ONCOGENE, (20110407), vol. 30, no. 14, doi:10.1038/onc.2010.549, ISSN 0950-9232, pages 1664 - 1680, XP055061288 [I] 1-20 * page 1665, column l, paragraph 2 - column r, paragraph 2 * * page 1667, column l, paragraph l - column r, paragraph 1 *

DOI:   http://dx.doi.org/10.1038/onc.2010.549
International search[X]US2011020368  (HYNES NANCY [CH]);
 [X]WO2012003189  (IRM LLC [US], et al);
 [Y]US2012027778  (GURNEY AUSTIN L [US])
Examination   - A. GURNEY ET AL, "Supporting information: Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20120702), vol. 109, no. 29, doi:10.1073/pnas.1120068109, ISSN 0027-8424, pages 1 - 3, XP055342843

DOI:   http://dx.doi.org/10.1073/pnas.1120068109
by applicantUS3773919
 US4485045
 US4544545
 US4816567
 US5013556
 US5750373
 WO2008031009
 WO2010037041
 US2011020368
 WO2012003189
    - WU; NUSSE, J. Biol. Chem., (20020000), vol. 277, pages 41762 - 9
    - MILLER et al., Oncogene, (19990000), vol. 18, pages 7860 - 72
    - JOHNSON et al., J. Bone Mineral Res., (20040000), vol. 19, page 1749
    - FUJIMORI et al., Cancer Res., (20010000), vol. 61, no. 18, pages 6656 - 9
    - SU et al., Ann. Surg. Oncol., (20060000), vol. 13, no. 12, pages 1604 - 9
    - GURNEY et al., PNAS, (20120000), vol. 109, no. 29, pages 11717 - 11722
    - PODE-SHAKKED et al., Oncogene, (20110000), vol. 30, pages 1664 - 1680
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - CLACKSON et al., Nature, (19910000), vol. 352, pages 624 - 628
    - MARKS et al., J. Mol. Biol., (19910000), vol. 222, pages 581 - 597
    - COLE et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, (19850000), page 77
    - BOEMER et al., J. Immunol., (19910000), vol. 147, no. 1, pages 86 - 95
    - VAUGHAN et al., Nat. Biotech., (19960000), vol. 14, pages 309 - 314
    - SHEETS et al., Proc. Nat'l. Acad. Sci., (19980000), vol. 95, pages 6157 - 6162
    - HOOGENBOOM; WINTER, J. Mol. Biol., (19910000), vol. 227, page 381
    - MARKS et al., J. Mol. Biol., (19910000), vol. 222, page 581
    - EPSTEIN et al., Proc. Natl. Acad. Sci. USA, (19850000), vol. 82, page 3688
    - HWANG et al., Proc. Natl. Acad. Sci. USA, (19800000), vol. 77, page 4030
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.